Valuation
- Market cap
- 45,827,000
- Revenue TTM
- $0
- Net income TTM
- $-21,440,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 231,600
- Avg volume
- 195,912
- Day's range
- $26.42 – $30.39
- Shares out
- 1,597,000
- Stochastic %K
- 31%
- Beta
- 1.42
- Analysts
- Strong Buy
- Price target
- $46.75
Company profile
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 20...
Show more
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 45 70 70 52 10
- Website
- https://galecto.com
- Address
- Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark
Latest news
No headlines yet.
